• Citer

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer

par Martin, Miguel;Bonneterre, Jacques;Geyer Jr., Charles C.E.;Ito, Yoshinori;Ro, Jungsil;Lang, Istvan;Kim, Sung-Bae;Germa, Caroline;Vermette, Jennifer;Wang, Kenneth;Wang, Kongming;Awada, Ahmad
Référence European journal of cancer, 49, 18, page (3763-3772)
Publication Publié, 2013-12

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer
Auteur:	Martin, Miguel; Bonneterre, Jacques; Geyer Jr., Charles C.E.; Ito, Yoshinori; Ro, Jungsil; Lang, Istvan; Kim, Sung-Bae; Germa, Caroline; Vermette, Jennifer; Wang, Kenneth; Wang, Kongming; Awada, Ahmad
Informations sur la publication:	European journal of cancer, 49, 18, page (3763-3772)
Statut de publication:	Publié, 2013-12
Sujet CREF:	Cancérologie
Mots-clés:	Breast
	phase II
MeSH keywords:	Adult
	Aged
	Aged, 80 and over
	Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use
	Breast Neoplasms -- drug therapy -- metabolism -- pathology
	Deoxycytidine -- administration & dosage -- adverse effects -- analogs & derivatives
	Diarrhea -- chemically induced
	Disease-Free Survival
	Drug Administration Schedule
	Female
	Fluorouracil -- administration & dosage -- adverse effects -- analogs & derivatives
	Humans
	Kaplan-Meier Estimate
	Middle Aged
	Nausea -- chemically induced
	Quinazolines -- administration & dosage -- adverse effects
	Quinolines -- adverse effects -- therapeutic use
	Receptor, ErbB-2 -- metabolism
	Treatment Outcome
	Vomiting -- chemically induced
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0959-8049
	info:doi/10.1016/j.ejca.2013.07.142
	info:pii/S0959804913007181
	info:scp/84888004978
	info:pmid/23953056